Skip to main content

Table 4 Univariate and multivariate statistical analysis of cancer specific survival

From: Survival and prognostic factors for survival, cancer specific survival and disease free interval in 239 patients with Hurthle cell carcinoma: a single center experience

  Univariate Multivariate
Factor p OR 95% CI p OR 95% CI
Gender (male vs. female) 0,126 0,42 0,13–1,28    
Age (years) (<54 vs. ≥55) 0,056 3,3 0,97–11,26    
Disease duration (years) (<5 vs. ≥5) 0,941 1,04 0,34–3,19    
T stadium (T1 and T2 vs. T3 and T4) 0,03 4,18 1,14–15,19    
N stadium (N0 and Nx vs. N1a and N1b) 0,451 2,19 0,28–16,98    
Tumor type (minimally vs. widely invasive) 0,684 0,78 0,24–2,54    
Tumor size (mm) (≤39 vs. >40) 0,328 1,99 0,49–7,99    
Capsular invasion (positive vs. no or minimal) 0,903 1,09 0,29–4,07    
Vascular invasion (positive vs. no or minimal) 0,149 0,22 0,03–1,71    
Number of tumor focuses (one vs. multicentric) 0,374 1,72 0,52–5,73    
Affection of both lobes (yes vs. no) 0,05 3,09 0,97–9,85 0,002 8,09 2,12–30,79
Regional tumor infiltration (yes vs. no) 0,027 0,28 0,92–0,86    
Primary procedure (total thyroidectomy vs. less than total) 0,049 3,24 0,99–10,64 0,002 8,46 2,21–32,31
Total thyroidectomy after lobectomy (yes vs. no) 0,118 0,3 0,68–1,35    
Type of procedure overall (total thyroidectomy vs. less than total) 0,817 1,17 0,31–4,31    
Reoperation due to relapse (yes vs. no) 0,001 0,117 0,04–0,35 0,001 0,10 0,03–0,39
Surgeon’s experience (years) (<10 vs. 10+) 0,421 0,63 0,2–1,95    
Radioiodine ablation (yes vs. no) 0,921 1,12 0,1–12,45    
Diabetes mellitus (yes vs. no) 0,603 21,78 0,001–2,393,431    
Hypertension (yes vs. no) 0,292 0,53 0,16–1,71    
Other malignancies (yes vs. no) 0,519 23,03 0,002–315,487    
Thyroglobulin (ng/mL) (<300 vs. >300) 0,695 1,62 0,14–18,38